NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

NTLA

Intellia Therapeutics Inc

Apr 21 • 10:46AM ET

8.26

Dollar change +1.03
Percentage change 14.25	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP BEAM EDIT BNTX SGMO REPL CLLS FDMT PSTX ADPT

| Held by: ARKK VTI ARKG IWM VB XBI VXF VBK IWN IBB

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-5.25	Insider Own	5.89%	Shs Outstand	102.03M	Perf Week	11.47%
Market Cap	855.05M	Forward P/E	-	EPS next Y	-4.43	Insider Trans	-1.16%	Shs Float	97.42M	Perf Month	-5.06%
Income	-519.02M	PEG	-	EPS next Q	-1.28	Inst Own	90.13%	Short Float	27.65%	Perf Quarter	-13.05%
Sales	57.88M	P/S	14.77	EPS this Y	10.69%	Inst Trans	-1.15%	Short Ratio	7.90	Perf Half Y	-59.86%
Book/sh	8.55	P/B	0.97	EPS next Y	5.60%	ROA	-41.66%	Short Interest	26.94M	Perf Year	-61.58%
Cash/sh	5.81	P/C	1.42	EPS next 5Y	23.52%	ROE	-54.00%	52W Range	5.90 - 28.18	Perf YTD	-29.16%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-20.04%	ROI	-48.88%	52W High	-70.69%	Beta	2.28
Dividend TTM	-	Quick Ratio	5.77	Sales past 5Y	15.68%	Gross Margin	82.23%	52W Low	40.00%	ATR (14)	0.76
Dividend Ex-Date	-	Current Ratio	5.77	EPS Y/Y TTM	3.09%	Oper. Margin	-923.10%	RSI (14)	53.22	Volatility	7.99% 9.45%
Employees	403	Debt/Eq	0.24	Sales Y/Y TTM	59.55%	Profit Margin	-896.77%	Recom	1.64	Target Price	40.88
Option/Short	Yes / Yes	LT Debt/Eq	0.22	EPS Q/Q	13.38%	Payout	-	Rel Volume	2.46	Prev Close	7.23
Sales Surprise	50.50%	EPS Surprise	4.56%	Sales Q/Q	771.57%	Earnings	Feb 27 BMO	Avg Volume	3.41M	Price	8.26
SMA20	11.10%	SMA50	-8.22%	SMA200	-47.30%	Trades		Volume	1,975,223	Change	14.25%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Upgrade	Wolfe Research	Peer Perform → Outperform	$21
Mar-05-25	Initiated	H.C. Wainwright	Buy	$30
Feb-28-25	Downgrade	JP Morgan	Overweight → Neutral	$45 → $13
Feb-28-25	Downgrade	Goldman	Neutral → Sell	$9
Jan-27-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$56 → $11
Feb-23-24	Downgrade	Goldman	Buy → Neutral	$136 → $32
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Apr-13-23	Initiated	Canaccord Genuity	Buy	$66
Mar-21-23	Initiated	Bernstein	Outperform	$54
Mar-14-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$54 → $57
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$67
Jan-24-23	Upgrade	Citigroup	Sell → Neutral	$48 → $39
Jan-19-23	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Oct-11-22	Initiated	Morgan Stanley	Overweight	$84
Sep-21-22	Initiated	JP Morgan	Overweight	$85
Sep-01-22	Initiated	Citigroup	Sell	$50
Jun-17-22	Initiated	BMO Capital Markets	Market Perform	$54
Jun-16-22	Initiated	BofA Securities	Buy	$70
Apr-28-22	Initiated	Credit Suisse	Outperform	$100
Feb-18-22	Initiated	William Blair	Outperform	$144

Show Previous Ratings

Apr-11-25 05:45AM	Intellia Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA (PR Newswire) +9.45%
Apr-09-25 09:42AM	Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple (Insider Monkey) +12.74%
Apr-04-25 01:42PM	Intellia Therapeutics, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky for More Information NTLA (GlobeNewswire)
07:28AM	Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN (Clinical Trials Arena)
Apr-03-25 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.62%
12:40PM	Loading…
12:40PM	IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility (Pharmaceutical Technology)
07:30AM	Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy (GlobeNewswire)
Apr-01-25 12:41PM	Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy? (Insider Monkey) -6.40%
11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks)
Mar-31-25 10:10AM	Intellia Focuses on Pipeline Development Amid Stiff Competition (Zacks) -11.90%
Mar-28-25 09:39AM	Promising Genomics & Synthetic Biology Stocks to Consider in 2025 (Zacks)
06:24AM	Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication (Seeking Alpha)
Mar-27-25 11:36AM	NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication (Zacks)
Mar-26-25 07:30AM	Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy (GlobeNewswire)
Mar-21-25 11:25AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
10:27AM	Loading…
Mar-19-25 10:27AM	CRISPR Therapeutics Stock Trades Near 52-Week Low: Time to Buy or Sell? (Zacks)
Mar-05-25 09:34AM	Royal Caribbean upgraded, AppLovin downgraded: Wall Street's top analyst calls (The Fly)
Mar-04-25 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-28-25 06:01AM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) -7.09%
02:10AM	Intellia Therapeutics Inc (NTLA) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
01:17AM	Q4 2024 Intellia Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-25 08:45AM	Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Feb-26-25 08:56PM	Robbins LLP Reminds Intellia Therapeutics, Inc. (NTLA) Investors with Large Losses to Contact the Firm to Learn How They Can Recover for Their Losses (PR Newswire)
Feb-25-25 05:45AM	Investors in Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA (PR Newswire) -6.95%
Feb-24-25 10:00AM	2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street (Motley Fool) -5.42%
Feb-20-25 10:00AM	Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
09:57AM	Intellia Therapeutics (NTLA) Stock Jumps 6.5%: Will It Continue to Soar? (Zacks)
07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates (GlobeNewswire)
Feb-18-25 05:45AM	Intellia Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA (PR Newswire) +7.76%
02:08PM	Loading…
Feb-14-25 02:08PM	Intellia Therapeutics (NTLA): Among The SmallCap Stocks Insiders Are Selling Recently (Insider Monkey) +11.00%
09:55AM	Does Intellia Therapeutics (NTLA) Have the Potential to Rally 422.41% as Wall Street Analysts Expect? (Zacks)
Feb-06-25 08:10PM	Intellia Therapeutics Inc. (NTLA): Among Cathie Woods Top Stock Picks for 2025 (Insider Monkey)
Feb-04-25 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.25%
Jan-23-25 09:14AM	Intellia doses first subject in trial of NTLA-2002 for hereditary angioedema (Clinical Trials Arena)
Jan-22-25 07:30AM	Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (GlobeNewswire) +10.76%
05:00AM	Intellia makes progress on HAE study; 2 more China drug deals (BioPharma Dive)
Jan-13-25 03:00AM	Intellia slashes workforce by 27% to focus on late stage CRISPR candidates (Pharmaceutical Technology)
Jan-11-25 10:20AM	Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital (TipRanks)
07:36AM	Intellia Therapeutics price target lowered to $60 from $70 at Wells Fargo (TipRanks)
Jan-10-25 01:30PM	Why Is Intellia Therapeutics Stock Trading Lower On Friday? (Benzinga) -15.14%
03:58AM	Intellia to stop work on rare disease therapy, lay off staff (BioPharma Dive)
Jan-09-25 04:00PM	Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z) (GlobeNewswire)
Jan-06-25 07:30AM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.52%
Dec-30-24 03:51PM	Why Is Intellia Therapeutics, Inc. (NTLA) Among the Top CRISPR Stocks to Invest In? (Insider Monkey)
Dec-29-24 06:41AM	Intellia Therapeutics, Inc. (NTLA): Is This Gene Therapy Stock a Good Buy Right Now? (Insider Monkey)
Dec-11-24 11:57AM	Why Intellia Therapeutics (NTLA) Is the Worst ARK Stock to Buy According to Short Sellers (Insider Monkey)
Dec-03-24 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.87%
Nov-25-24 04:16PM	BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug (Investor's Business Daily)
07:30AM	Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy (GlobeNewswire)
Nov-22-24 08:30AM	Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock? (Motley Fool)
Nov-19-24 07:27AM	Intellia Therapeutics Announces Promising CRISPR Therapy Results (TipRanks)
06:54AM	ReCode to secure funds for cystic fibrosis gene correction treatments (Pharmaceutical Technology)
06:30AM	Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo (TipRanks)
Nov-18-24 10:24AM	Intellias gene editing therapy shows early potential in rare heart condition (Clinical Trials Arena)
06:53AM	CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest (BioPharma Dive)
Nov-16-24 10:16AM	Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis (GlobeNewswire)
Nov-11-24 12:59PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
12:45PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
Nov-08-24 12:01PM	Intellia Therapeutics Inc (NTLA) Q3 2024 Earnings Call Highlights: Financial Stability and ... (GuruFocus.com)
Nov-07-24 08:55AM	Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Nov-06-24 09:45AM	Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day? (Motley Fool)
Nov-05-24 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-04-24 08:00AM	This Beaten-Down Stock Could Soar by 354%, According to Wall Street (Motley Fool)
Oct-31-24 07:30AM	Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024 (GlobeNewswire)
03:59AM	Intellia Therapeutics (NTLA): Promising Gene Editing Stock with CRISPR-Cas9 Therapies (Insider Monkey)
Oct-26-24 05:19PM	Intellia Therapeutics Advances with Promising Phase 2 Results (TipRanks)
Oct-25-24 11:02AM	Intellia reports positive data from Phase II study of NTLA-2002 for HAE (Clinical Trials Arena)
08:16AM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
Oct-24-24 07:22PM	Why Intellia Therapeutics Stock Plummeted by 20% Today (Motley Fool) -20.51%
12:17PM	Intellia's Ntla-2002 Shows Promising Results, but Stock Drops Following Phase 2 Data Release (GuruFocus.com)
11:26AM	Intellia Therapeutics stock plunges after phase 2 results from NTLA-2002 study (Investing.com)
08:01AM	Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE) (GlobeNewswire)
07:17AM	Intellia data spark debate about CRISPR drugs potential (BioPharma Dive)
Oct-17-24 10:01AM	Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
06:30AM	This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street (Motley Fool)
Oct-16-24 03:51PM	Is Intellia Therapeutics, Inc. (NTLA) the Most Promising Biotech Stock According to Hedge Funds? (Insider Monkey) +5.43%
03:51PM	Intellia Therapeutics, Inc. (NTLA) the Most Promising Biotech Stock According to Hedge Funds? (Insider Monkey)
Oct-10-24 07:30AM	Intellia Therapeutics Announces New Date for Upcoming Investor Webcast (GlobeNewswire)
Oct-09-24 05:32PM	Intellia Therapeutics Inc (NTLA) Q2 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
06:35AM	2 Cathie Wood Stocks That Could Soar 32% and 282%, According to Wall Street (Motley Fool)
Oct-08-24 10:15AM	Intellia Therapeutics begins Phase III trial of hereditary angioedema gene therapy (Clinical Trials Arena)
Oct-07-24 07:30AM	Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE) (GlobeNewswire)
07:15AM	Intellia starts late-stage test of CRISPR therapy for rare swelling disease (BioPharma Dive)
Oct-03-24 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-01-24 07:30AM	Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions (GlobeNewswire) -6.57%
Sep-29-24 05:44AM	2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk (Motley Fool)
Sep-12-24 01:01PM	The Brawl Taking Shape Over Pfizers Multibillion-Dollar Heart Monopoly (The Wall Street Journal)
07:30AM	Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting (GlobeNewswire)
Sep-03-24 04:30PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-14-24 10:29AM	Intellia Therapeutics, Inc. (NTLA): Pioneering Gene Editing Solutions for Health Advancements (Insider Monkey)
Aug-09-24 11:32AM	Intellia's (NTLA) Q2 Earnings & Revenues Fall Shy of Estimates (Zacks)
10:19AM	3 Gene Editing Stocks with Potential to Transform Medicine (InvestorPlace)
Aug-08-24 07:01PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) +5.02%
12:23PM	Merck TIGIT drug fails another trial; Intellia therapy succeeds in HAE study (BioPharma Dive)
08:55AM	Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Aug-06-24 12:48PM	The 3 Best Cathie Wood Stocks to Buy in August 2024 (InvestorPlace)
Aug-01-24 11:15AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Clark Eliana	EVP, Chief Technical Officer	Mar 04 '25	Sale	8.99	679	6,104	95,369	Mar 04 04:43 PM
BASTA JAMES	EVP, General Counsel	Mar 04 '25	Sale	8.99	2,572	23,122	111,925	Mar 04 04:21 PM
Bhanji Muna	Director	Jan 29 '25	Sale	9.97	265	2,642	19,468	Jan 31 04:17 PM
Dube Michael P	VP, Chief Accounting Officer	Jan 03 '25	Sale	12.18	1,372	16,711	45,640	Jan 07 05:23 PM
BASTA JAMES	EVP, General Counsel	Jan 03 '25	Sale	12.18	7,074	86,161	74,497	Jan 07 05:22 PM
Lebwohl David	EVP, Chief Medical Officer	Jan 03 '25	Sale	12.18	9,557	116,404	87,666	Jan 07 05:20 PM
Hicks Derek	EVP, Chief Business Officer	Jan 03 '25	Sale	12.18	6,502	79,194	59,878	Jan 07 05:20 PM
LEONARD JOHN M	President and CEO	Jan 03 '25	Sale	12.18	26,807	326,509	941,115	Jan 07 05:19 PM
Sepp-Lorenzino Laura	EVP, Chief Scientific Officer	Jan 03 '25	Sale	12.18	8,966	109,206	77,388	Jan 07 05:16 PM
Clark Eliana	EVP, Chief Technical Officer	Jan 03 '25	Sale	12.18	7,422	90,400	64,048	Jan 06 04:16 PM
Clark Eliana	EVP, Chief Technical Officer	Jan 02 '25	Sale	12.03	556	6,689	71,470	Jan 06 04:16 PM
Dube Michael P	VP, Chief Accounting Officer	Oct 02 '24	Sale	19.01	2,012	38,248	47,012	Oct 04 05:29 PM
Clark Eliana	EVP, Chief Technical Officer	Jul 01 '24	Sale	22.93	405	9,287	71,470	Jul 03 01:15 PM
Verwiel Frank	Director	Jun 17 '24	Sale	25.00	1,505	37,625	17,948	Jun 20 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NTLA

Intellia Therapeutics Inc

Upgrade your FINVIZ experience